Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.40 |
| ▸ | KAT7 | O95251 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341219 | 0.90 | HCRTR1 (0.42) | KAT7USP30GPR119KAT8ABHD6 | |
| SCHEMBL3495223 | 0.89 | CNR2 (0.38) | TP53MAPT | |
| SCHEMBL3491499 | 0.89 | KAT7 (0.40) | KAT7USP30GPR119KAT8ABHD6 | |
| SCHEMBL8235764 | 0.89 | KAT7 (0.39) | KAT7USP30GPR119KAT8ACKR3 | |
| SCHEMBL13341002 | 0.89 | KAT7 (0.40) | KAT7USP30GPR119KAT8ACKR3 | |
| SCHEMBL13341218 | 0.88 | PARP1 (0.39) | KAT7USP30GPR119KAT8ABHD6 | |
| SCHEMBL8236038 | 0.87 | KAT7 (0.40) | KAT7USP30GPR119KAT8ABHD6 | |
| SCHEMBL13341187 | 0.85 | KAT7 (0.39) | KAT7USP30GPR119KAT8ACKR3 | |
| SCHEMBL8238421 | 0.85 | KAT7 (0.39) | KAT7USP30GPR119KAT8ABHD6 | |
| SCHEMBL3492043 | 0.83 | GPR119 (0.39) | KAT7USP30GPR119KAT8TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | YAP1 500/4885KAT7 1058/4885USP30 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.